



# JAPAN

## Number of new cases

**1 005 157**

## Number of deaths

**426 278**

## Number of prevalent cases (5-year)

**2 741 718**


### Statistics at a glance, 2022

	Males	Females	Both sexes
<b>Population</b>	61 295 634	64 289 205	125 584 839
<b>Incidence*</b>			
Number of new cancer cases	580 535	424 622	1 005 157
Age-standardized incidence rate	309.8	234.2	267.1
Risk of developing cancer before the age of 75 years (cum. risk %)	30.9	22.1	26.4
Top 3 leading cancers (ranked by cases)**	Prostate Lung Stomach	Breast Colorectum Stomach	Colorectum Lung Stomach
<b>Mortality*</b>			
Number of cancer deaths	240 823	185 455	426 278
Age-standardized mortality rate	100.7	61.3	78.6
Risk of dying from cancer before the age of 75 years (cum. risk %)	9.7	5.8	7.7
Top 3 leading cancers (ranked by deaths)**	Lung Colorectum Stomach	Colorectum Lung Pancreas	Lung Colorectum Stomach
<b>Prevalence*</b>			
5-year prevalent cases	1 520 054	1 221 664	2 741 718



### Top 5 most frequent cancers\*\*

#### Males




Total: 580 535

Rank	Cancer site	Number of cases	Percent
1st	Prostate	104 318	18.0%
2nd	Lung	95 740	16.5%
3rd	Stomach	84 071	14.5%
4th	Colorectum	80 435	13.9%
5th	Liver	28 678	4.9%
-	Others	187 293	32.3%

Number of new cases in 2022, males, all ages

#### Females




Total: 424 622

Rank	Cancer site	Number of cases	Percent
1st	Breast	91 916	21.6%
2nd	Colorectum	65 321	15.4%
3rd	Stomach	42 653	10.0%
4th	Lung	40 983	9.7%
5th	Pancreas	24 018	5.7%
-	Others	159 731	37.6%

Number of new cases in 2022, females, all ages

#### Both sexes



Total: 1 005 157

Rank	Cancer site	Number of cases	Percent
1st	Colorectum	145 756	14.5%
2nd	Lung	136 723	13.6%
3rd	Stomach	126 724	12.6%
4th	Prostate	104 318	10.4%
5th	Breast	91 916	9.1%
-	Others	399 720	39.8%

Number of new cases in 2022, both sexes, all ages

Incidence, Mortality and Prevalence by cancer site

Cancer	New cases				Deaths				5-year prevalence	
	Number	Rank	(%)	Cum.risk	Number	Rank	(%)	Cum.risk	Number	Prop. (per 100 000)
Colorectum	145 756	1	14.5	4.3	60 473	2	14.2	1.2	455 154	16.6
Lung	136 723	2	13.6	3.6	83 243	1	19.5	1.5	145 679	5.3
Stomach	126 724	3	12.6	3.3	43 807	3	10.3	0.70	344 835	12.6
Prostate	104 318	4	10.4	6.3	14 095	8	3.3	0.29	410 384	15.0
Breast	91 916	5	9.1	7.8	17 638	6	4.1	1.1	389 650	14.2
Pancreas	47 627	6	4.7	1.1	43 265	4	10.1	0.87	32 262	1.2
Liver	41 388	7	4.1	1.1	26 420	5	6.2	0.41	73 347	2.7
NHL	36 179	8	3.6	1.0	15 408	7	3.6	0.24	108 716	4.0
Bladder	34 568	9	3.4	0.78	10 928	10	2.6	0.12	107 730	3.9
Kidney	21 207	10	2.1	0.78	6 926	13	1.6	0.14	67 470	2.5
Oesophagus	19 926	11	2.0	0.61	12 161	9	2.9	0.31	23 162	0.85
Corpus uteri	18 338	12	1.8	1.6	3 630	18	0.85	0.22	75 593	2.8
Thyroid	16 419	13	1.6	0.74	2 193	21	0.51	0.03	59 812	2.2
Leukaemia	13 572	14	1.4	0.52	10 066	11	2.4	0.23	41 547	1.5
Lip, oral cavity	11 088	15	1.1	0.35	3 846	17	0.90	0.06	34 728	1.3
Cervix uteri	10 958	16	1.1	1.2	3 864	16	0.91	0.27	41 210	1.5
Gallbladder	10 814	17	1.1	0.19	7 252	12	1.7	0.10	10 202	0.37
Ovary	10 693	18	1.1	0.93	5 301	14	1.2	0.33	33 732	1.2
Multiple myeloma	6 988	19	0.70	0.17	4 827	15	1.1	0.07	18 762	0.68
Brain CNS	5 361	20	0.53	0.22	3 169	19	0.74	0.12	21 346	0.78
Larynx	5 156	21	0.51	0.18	1 001	24	0.24	0.02	17 238	0.63
Hypopharynx	4 646	22	0.46	0.19	2 238	20	0.53	0.06	9 180	0.34
Oropharynx	2 876	23	0.29	0.12	1 413	23	0.33	0.04	8 499	0.31
Testis	2 276	24	0.23	0.29	72	32	0.02	0.01	10 315	0.38
Mesothelioma	2 137	25	0.21	0.07	1 729	22	0.41	0.04	2 355	0.09
Hodgkin lymphoma	1 847	26	0.18	0.09	254	29	0.06	0.01	6 403	0.23
Salivary glands	1 773	27	0.18	0.07	696	26	0.16	0.02	5 911	0.22
Melanoma	1 622	28	0.16	0.05	747	25	0.18	0.02	5 996	0.22
Vulva	1 341	29	0.13	0.05	328	28	0.08	0.01	3 929	0.14
Nasopharynx	780	30	0.08	0.03	367	27	0.09	0.01	2 517	0.09
Penis	584	31	0.06	0.03	177	30	0.04	0.01	1 773	0.07
Vagina	378	32	0.04	0.02	170	31	0.04	0.01	949	0.04
<b>All cancers</b>	<b>1 005 157</b>	-	-	<b>26.4</b>	<b>426 278</b>	-	-	<b>7.7</b>	<b>2 741 718</b>	-
<b>All cancers excl. NMSC</b>	<b>992 806</b>	-	-	<b>26.3</b>	<b>425 025</b>	-	-	<b>7.7</b>	<b>2 699 456</b>	-

Data source and methods

Incidence



Country-specific data source: No data  
 Method: Estimated from national mortality estimates by modelling, using mortality:incidence ratios derived from survival estimation

Mortality

Country-specific data source: National (WHO)  
 Method: National rates projected to 2022

Prevalence

Computed using sex-, site- and age-specific incidence to 1-,3- and 5-year prevalence ratios from Nordic countries for the period (2011-2020), and scaled using Human Development Index (HDI) ratios.



\* includes non-melanoma skin cancer (NMSC)

\*\* NMSC included in other cancers

Age standardization using world population ([see link](#))

References

Website citation

Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: <https://gco.iarc.who.int/today>, accessed [DD Month YYYY].

Cancer incidence and mortality data

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 Feb 4. doi: 10.3322/caac.21660. Epub ahead of print. PMID: 33538338.

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021 Apr 5. doi: 10.1002/ijc.33588. Epub ahead of print. PMID: 33818764.

